Brussels, Belgium, March 1, 2014

Merodis, an independent corporate finance advisory firm, is pleased to announce that it successfully advised Brussels-based ERFA SA related to the sale of its pharmaceutical business, assets and liabilities to Bepharbel SA, a company created by Jean Stéphenne and a group of experienced players in the pharma industry, supported by private investors.
The pharmaceutical business of ERFA generates sales between EUR 4m and EUR 5m per year. ERFA pharmaceutical assets include, among others, two combinations of antibiotics indicated against local bacterial infections, which are well established products in Belgium and Luxemburg, i.e. best-selling Neobacitracine and ophthalmic ointment Aureomycine. The acquisition also includes a series of other products as well as the GMP contract manufacturing business of ERFA for leading pharmaceutical companies. The portfolio of products sold to Bepharbel attracted significant interest from potential buyers. The price of the transaction was not communicated.
By this transaction, Merodis confirms its strong position in Belgium for M&A transactions in the area of pharma and OTC/OTX companies and products.

For more information, please contact:

Rodolphe Blondiau
rbl@merodis.com , +32 488 81 45 07
Thierry Hazevoets
tha@merodis.com , + 23 495 58 68 98
Dirk Marckx
dma@merodis.com , +32 495 38 17 81